Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study is to determine the efficacy of the Microbio InfectID-BSI qPCR kit in a clinical laboratory environment using patient whole blood for pathogen detection and identification versus standard of care methods from blood culture.
The objective of this study is to determine the sensitivity and specificity of the Microbio InfectID-BSI qPCR kit by the evaluation of clinical blood samples versus standard of care methods from blood culture.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| InfectID-BSI (Bloodstream Infection) qPCR Assay | Diagnostic Test | InfectID-BSI technology targets nucleic acid sequences unique to the target analyte. The qPCR raw data collected from InfectID-BSI's 9 assay tubes is analysed by Microbio's InfectID-Client (InfectID-BSI-associated software) and the result is reported as an analyte-detection if the unique target analyte is present or no result if the unique target analyte is absent. InfectID-BSI is carried out with whole blood from a venous puncture (EDTA). DNA is extracted from a sample of the collected blood using a validated DNA extraction instrument according to the manufacturer's instructions. The extracted DNA is then added to the InfectID-BSI qPCR reagent panel which consists of 9 reaction tubes (6 for bacteria, and 3 for yeast species). The panel is subjected to real-time qPCR using a process of Melt Curve analysis using the Rotor-Gene Q MDx qPCR instrument. The assay report identifies the species present in the sample upon completion. Results are generated within 3 hours. |
| Measure | Description | Time Frame |
|---|---|---|
| Determine the sensitivity and specificity of InfectID-BSI versus blood culture. | The objective of this study is to determine the sensitivity and specificity of the Microbio InfectID-BSI qPCR kit by the evaluation of clinical blood samples versus standard of care methods from blood culture. | Through study completion, an average of 1 year |
| Determine the efficacy of detection and identification of the 26-pathogen panel in the InfectID-BSI assay versus standard of care blood culture. Using qPCR - a new molecular technology to identify the top 20 bacterial and 6 yeast sepsis causing species. | The objective of the study is to determine the efficacy of the Microbio InfectID-BSI qPCR kit in a clinical laboratory environment using patient whole blood for pathogen detection and identification versus standard of care methods from blood culture. InfectID has it's own reporting software - InfectID-Client which is how the InfectID-BSI results will be reported for the study. | Through study completion, an average of 1 year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The study seeks to enroll neonates (less than 1 month of age), pediatrics (between 1 month and 17 years of age) and adults (>18 years of age) who are suspected to have a blood stream infection (BSI /Sepsis).
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Naomi DeFazio | Contact | +61410661035 | NDeFazio@microbio.com.au |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Indiana University Hospital | Indianapolis | Indiana | 46202 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An additional 2 x EDTA tube will be collected at the same time as routine bloods are collected for suspected sepsis. One EDTA tube will be collected for the purposes of testing on the InfectID-BSI assay, and the 2nd EDTA tube will be collected for the purposes of storing the sample to aid in DNA sequencing for discordant results between InfectID-BSI and standard of care blood cultures.
| University of Maryland | Baltimore | Maryland | 21201 | United States |
|
| TriCore Reference Laboratories | Albuquerque | New Mexico | 87102 | United States |
|
| Vanderbilt University Medical Centre | Nashville | Tennessee | 37232 | United States |
|
| Texas Children's Hospital | Houston | Texas | 77030 | United States |
| The Prince Charles Hospital | Chermside | Queensland | 4032 | Australia |
|
| The Princess Alexandra Hospital | Woolloongabba | Queensland | 4102 | Australia |
|
| Southwest Regional Laboratory, UK Health Security Agency, Bristol UK | Bristol | United Kingdom |
|
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D012772 | Shock, Septic |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
Not provided
Not provided